PIP Search Page

Displaying 1 - 20 of 595

PIPS Search Results
PIP Number	Active Substance	Conditions / Indications	Invented Name	Therapeutic area	Decision Type	Compliance Check Sort descending	Date Published
MHRA-100023-PIP01-21-M01 (update)	bimekizumab	Treatment of psoriasis	Bimzelx	Dermatology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	03/11/2021
MHRA-100025-PIP01-21-M01 (update)	LAROTRECTINIB	Treatment of malignant neoplasms of the central nervous system	VITRAKVI	Oncology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	03/11/2021
MHRA-100036-PIP01-21-M01 (update)	FERRIC MALTOL	Treatment of Iron deficiency anaemia (IDA)	FERACCRU FERACCRU ACCRUFER FERACCRU	Haematology-Hemostaseology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	03/11/2021
MHRA-100055-PIP01-21	Edaravone	Treatment of Amyotrophic lateral sclerosis	Radicava Radicut Radicut Radicut	Neurology	W: decision granting a waiver in all age groups for the listed condition(s).	No	03/11/2021
MHRA-100067-PIP01-21-M01 (update)	nirsevimab (MEDI8897) (Anti-respiratory syncytial virus human IgG1κ monoclonal antibody)	Prevention of lower respiratory tract infection caused by respiratory syncytial virus (RSV).		Infectious diseases Vaccines	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	03/11/2021
MHRA-100083-PIP01-21-M01 (update)	Human Fibrinogen (INN) / Human Thrombin (INN) HUMAN THROMBIN HUMAN FIBRINOGEN	Treatment of: haemorrhage from a surgical procedure CSF leakage from a neurosurgical procedure	EVICEL, Solution for sealant EVARREST, Sealant matrix (withdrawn EU MAA) EVICEL EVICEL EVICEL	Other: blood-derived topical haemostats	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	15/11/2021
MHRA-100173-PIP01-21	PACLITAXEL	Treatment of soft tissue sarcoma	Paxorlea	Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	17/11/2021
MHRA-100174-PIP01-21	Encequidar	Treatment of breast cancer Treatment of soft tissue sarcoma	Paxorlea	Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	17/11/2021
MHRA-100049-PIP01-21-M01 (update)	IBRUTINIB	Treatment of mature B-cell neoplasm	Imbruvica Imbruvica Imbruvica Imbruvica Imbruvica Imbruvica Imbruvica Imbruvica Imbruvica Imbruvica Imbruvica	Oncology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	17/11/2021
MHRA-100059-PIP01-21-M01 (update)	roxadustat	Treatment of anaemia due to chronic disorders	EVRENZO EVRENZO	Haematology-Hemostaseology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	03/12/2021
MHRA-100024-PIP01-21-M01 (update)	LAROTRECTINIB	Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms)	VITRAKVI	Oncology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	03/12/2021
MHRA-100092-PIP01-21-M01 (update)	VENETOCLAX	Haematopoietic and lymphoid malignant neoplasms Treatment of solid tumour malignant neoplasms		Oncology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	03/12/2021
MHRA-100152-PIP01-21	cosibelimab	Treatment of cutaneous squamous cell carcinoma		Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	03/12/2021
MHRA-100235-PIP01-21-M01 (update)	Sotrovimab	Treatment of coronavirus disease 2019 (COVID-19)	Xevudy	Infectious diseases	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	03/12/2021
MHRA-100102-PIP01-21-M01 (update)	MOMETASONE FUROATE INDACATEROL ACETATE	Treatment of asthma	Atectura Breezhaler Atectura Breezhaler and its duplicate authorisation Bemrist Breezhaler Atectura Breezhaler Atectura Breezhaler Atectura Breezhaler Atectura Breezhaler and its duplicate authorisation Bemrist Breezhaler Atectura Breezhaler and its duplicate authorisation Bemrist Breezhaler Atectura Breezhaler and its duplicate authorisation Bemrist Breezhaler Atectura Breezhaler and its duplicate authorisation Bemrist Breezhaler Atectura Breezhaler and its duplicate authorisation Bemrist Breezhaler	Pneumology - Allergology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	17/12/2021
MHRA-100040-PIP01-21-M01 (update)	Cotadutide	Treatment of Type 2 Diabetes Mellitus		Endocrinology-Gynaecology-Fertility-metabolism	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	17/12/2021
MHRA-100074-PIP01-21	GABAPENTIN	Treatment of Postherpetic Neuralgia	Gralise	Neurology Pain	W: decision granting a waiver in all age groups for the listed condition(s).	No	17/12/2021
MHRA-100081-PIP01-21	Zibotentan DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE	Treatment of Chronic Kidney Disease	Not available at present	Other: Renal Disease	W: decision granting a waiver in all age groups for the listed condition(s).	No	17/12/2021
MHRA-100094-PIP01-21-M01 (update)	DORAVIRINE LAMIVUDINE TENOFOVIR DISOPROXIL FUMARATE	Treatment of human immunodeficiency virus-1 (HIV-1) infection	Delstrigo	Infectious diseases	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	17/12/2021
MHRA-100095-PIP01-21-M01 (update)	DORAVIRINE	Treatment of human immunodeficiency virus-1 (HIV-1) infection	Pifeltro	Infectious diseases	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	17/12/2021

Download XLSX

Search Filters: